Namodenoson study for severe fatty liver disease cleared for US
Can-Fite BioPharma has been approved to enroll U.S. patients in its ongoing Phase 2b clinical trial of the oral treatment candidate namodenoson in people…
Two scores calculated from blood biomarkers can accurately discriminate between pregnant women with intrahepatic cholestasis of pregnancy (ICP) and those without, and predict ICP-associated complications, according to a study from Moldova. “This study provides valuable information to help clinicians better diagnose and perform the management of intrahepatic cholestasis of…
Read MoreCan-Fite BioPharma has been approved to enroll U.S. patients in its ongoing Phase 2b clinical trial of the oral treatment candidate namodenoson in people…
A toddler boy with cirrhosis, or permanent liver scarring, due to Alagille syndrome developed a hepatoblastoma, a type of liver cancer that typically occurs…
A Phase 2a clinical trial testing Kezar Life Sciences’ investigational therapy zetomipzomib in adults with autoimmune hepatitis who did not respond well to standard…